Enanta Pharmaceuticals (ENTA) Revenue (2012 - 2026)
Enanta Pharmaceuticals' (ENTA) quarterly Revenue came in at $17.2 million in Q1 2026, up 14.96% YoY from $14.9 million in Q1 2025, and down 7.82% on a QoQ basis from $18.6 million in Q4 2025.
Enanta Pharmaceuticals (ENTA) Revenue (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals (ENTA) has 15 years of Revenue data on file, last reported at $17.2 million in Q1 2026.
- Quarterly Revenue rose 14.96% year-over-year to $17.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $69.2 million (up 7.37% YoY) and the FY2025 annual result came in at $65.3 million, down 3.42% from the prior year.
- Revenue slipped to $17.2 million in Q1 2026, from $18.6 million in the prior quarter.
- In the past five years, Revenue ranged from a high of $23.6 million in Q4 2022 to a low of $14.6 million in Q3 2024.
- A 5-year average of $18.0 million and a median of $18.0 million in 2023 frame the typical range for Revenue.
- Annual changes were most pronounced in 2023 — Revenue declined 23.67% — and 2026, when it climbed 14.96%.
- Tracing ENTA's Revenue over 5 years: stood at $23.6 million in 2022, then decreased by 23.67% to $18.0 million in 2023, then retreated by 5.8% to $17.0 million in 2024, then gained by 9.76% to $18.6 million in 2025, then fell by 7.82% to $17.2 million in 2026.
- The last three Revenue figures came in at $17.2 million (Q1 2026), $18.6 million (Q4 2025), and $15.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Enanta Pharmaceuticals | 383.29 Mn | 193.78 Mn | - | 14.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.36 Mn |
| Mar 31, 2026 | 17.16 Mn |
| Dec 31, 2025 | 18.62 Mn |
| Sep 30, 2025 | 15.13 Mn |
| Jun 30, 2025 | 18.31 Mn |
| Mar 31, 2025 | 14.93 Mn |
| Dec 31, 2024 | 16.96 Mn |
| Sep 30, 2024 | 14.61 Mn |
| Jun 30, 2024 | 17.97 Mn |
| Mar 31, 2024 | 17.05 Mn |
| Dec 31, 2023 | 18.00 Mn |
| Sep 30, 2023 | 18.93 Mn |
| Jun 30, 2023 | 18.89 Mn |
| Mar 31, 2023 | 17.80 Mn |
| Dec 31, 2022 | 23.59 Mn |
| Sep 30, 2022 | 20.32 Mn |
| Jun 30, 2022 | 19.48 Mn |
| Mar 31, 2022 | 18.72 Mn |
| Dec 31, 2021 | 27.65 Mn |
| Sep 30, 2021 | 23.58 Mn |